To treat systolic dysfunction, a vector of the invention may include a transcriptional regulatory element from a gene such as the one encoding the Na + /Ca 2+ exchanger.
A combination of gene therapy vectors, each with a different transgene and at least one of which includes a regulatable transcriptional control element, is employed.